SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

2/9/22 2:26:01 PM ET

Medical/Dental Instruments

Health Care

Get the next $IRMD alert in real time by email

SC 13G/A 1 irmd13g2.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2 Name of Issuer: Iradimed Corp Title of Class of Securities: Common CUSIP Number: 46266A109 December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: /X/ Rule 13d-l(b) / / Rule 13d-l(c) / / Rule 13d-l(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP Number: 46266A109 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Nine Ten Capital Management LLC - IRS # 46-5220958 2. Check the Appropriate Box if a Member of a Group a. / / b. // 3. SEC Use Only 4. Citizenship or Place of Organization Evanston, IL 5. Sole Voting Power: 730,659 6. Shared Voting Power: 0 7. Sole Dispositive Power: 730,659 8. Shared Dispositive Power: 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 730,659 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9): 5.9% 12. Type of Reporting Person: IA -2- CUSIP Number: 46266A109 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Nine Ten Partners LP - IRS # 46-5301261 2. Check the Appropriate Box if a Member of a Group a. / / b. // 3. SEC Use Only 4. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 730,659 6. Shared Voting Power: 0 7. Sole Dispositive Power: 730,659 8. Shared Dispositive Power: 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 730,659 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9): 5.9% 12. Type of Reporting Person: PN -3- CUSIP Number: 46266A109 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Russell Mollen 2. Check the Appropriate Box if a Member of a Group a. / / b. // 3. SEC Use Only 4. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 730,659 6. Shared Voting Power: 0 7. Sole Dispositive Power: 730,659 8. Shared Dispositive Power: 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 730,659 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares / / 11. Percent of Class Represented by Amount in Row (9): 5.9% 12. Type of Reporting Person: HC -4- Item 1(a) Name of Issuer: Iradimed Corp (b) Address of Issuer's Principal Executive Offices: 1025 WILLA SPRINGS DR. WINTER SPRINGS FL 32708 Item 2(a) - (c). Name, Principal Business Address, and Citizenship of Persons Filing: (a) Name of Person Filing Nine Ten Capital Management LLC (b) Address of the Principal Office or, if none, residence 1603 Orrington Ave, Ste 1650 Evanston, IL 60201 (c) Citizenship United States (d) Title of Class of Securities: Common (e) CUSIP Number: 46266A109 Item 3. This statement is filed pursuant to Rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: / / Broker or Dealer registered under Section 15 of the Act. /x/ Investment Adviser in accordance with Section 240.13d-1 (b)(1)(ii)(E) Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. ~~(a) Amount beneficially owned 730,659 ----------------- (b) Percent of class 5.9% -----~~

(c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 730,659 ----------- (ii) Shared power to vote or to direct the vote 0 ----------- (iii) Sole power to dispose or to direct the 730,659 disposition of ----------- (iv) Shared power to dispose or to direct the 0 disposition of -----------

Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following //. Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A -5- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of the Group. N/A Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. By: Michelle Katauskas _____________________________ ___2-9-2022______________ Title: CCO/COO Date

Get the next $IRMD alert in real time by email

Date

Price Target

Rating

Analyst

4/12/2023

$50.00

Buy

Lake Street

SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

Chat with this insight

Recent Analyst Ratings for
$IRMD

$IRMD
Market Insights

Live Market Insights

IRadimed Announces Uplisting To The Nasdaq Global Market, Effective June 14, 2024

IRADIMED Expects Q2 Adjusted EPS Of $1.52-$1.62 Versus Consensus Of $1.38

IRADIMED Expects Q2 Revenues Of $17.6M-$17.8M Versus Consensus Of $17.88M

$IRMD
SEC Filings

SEC Form 144 filed by iRadimed Corporation

SEC Form 10-Q filed by iRadimed Corporation

iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$IRMD
Leadership Updates

Live Leadership Updates

IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

$IRMD
Press Releases

Fastest customizable press release news feed in the world

IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024

IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share

IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st

$IRMD
Large Ownership Changes

This live feed shows all institutional transactions in real time.